REGENXBIO Inc. (27)

Browse by Contract Category

Contracts

Compensation Program for Non-Employee Directors (Filed With SEC on August 3, 2022)
Letter Agreement dated March 21, 2022 between the Company and The Trustees of the University of Pennsylvania (Filed With SEC on May 4, 2022)
Settlement Agreement and Mutual Release dated November 12, 2021 between the Registrant and Abeona Therapeutics Inc (Filed With SEC on March 1, 2022)
Royalty Purchase Agreement dated December 22, 2020 between the Registrant and entities managed by Healthcare Royalty Management, LLC (Filed With SEC on March 1, 2021)
Fifth Amendment to License Agreement effective September 11, 2020 between the Company and The Trustees of the University of Pennsylvania (Filed With SEC on November 4, 2020)
Third Amendment to Lease dated October 30, 2020 between the Company and ARE-Maryland No. 24, LLC (Filed With SEC on November 4, 2020)
Description of Securities (Filed With SEC on March 1, 2022)
Collaboration and License Agreement dated September 10, 2021 between the Company and AbbVie Global Enterprises Ltd (Filed With SEC on November 2, 2021)
Form of Stock Option Award Agreement for the 2015 Equity Incentive Plan (Filed With SEC on March 1, 2021)
Form of Restricted Stock Unit Award Agreement for the 2015 Equity Incentive Plan (Filed With SEC on March 1, 2021)
Description of Securities (Filed With SEC on March 1, 2021)
Underwriting Agreement, dated January 7, 2021, among REGENXBIO Inc. and BofA Securities, Inc., Morgan Stanley & Co. LLC and Barclays Capital Inc., as representatives of the... (Filed With SEC on January 8, 2021)
Fifth Amendment to Lease dated October 30, 2020 between the Company and ARE-Maryland No. 45, LLC (Filed With SEC on November 4, 2020)
Compensation Program for Non-Employee Directors (Filed With SEC on November 4, 2020)
First Amendment to License Agreement dated November 4, 2019 between the Registrant and Abeona Therapeutics Inc (Filed With SEC on February 26, 2020)
Compensation Program for Non-Employee Directors (Filed With SEC on February 26, 2020)
Description of Securities (Filed With SEC on February 26, 2020)
Second Amendment to Lease dated November 4, 2019 between the Company and ARE-Maryland No. 24, LLC (Filed With SEC on November 5, 2019)
Compensation Program for Non-Employee Directors (Filed With SEC on August 7, 2019)
First Amendment to Lease dated May 28, 2019 between REGENXBIO Inc. and DS400OWNER, LLC (Filed With SEC on June 3, 2019)
Lease dated May 16, 2016 between REGENXBIO Inc. and DS400OWNER, LLC, as successor-in-interest to 400 Madison Holdings, LLC (Filed With SEC on June 3, 2019)
First Amendment to Lease dated April 23, 2019 between the Company and ARE-Maryland No. 24, LLC (Filed With SEC on May 7, 2019)
Letter Agreement to Lease dated April 12, 2019 between the Company and ARE-Maryland No. 24, LLC (Filed With SEC on May 7, 2019)
Fourth Amendment to License Agreement effective April 4, 2019 between the Company and The Trustees of the University of Pennsylvania (Filed With SEC on May 7, 2019)
Employment Agreement effective April 17, 2019 between the Company and Steve Pakola, M.D (Filed With SEC on May 7, 2019)
License Agreement dated November 4, 2018 between the Registrant and Abeona Therapeutics Inc (Filed With SEC on February 27, 2019)
Compensation Program for Non-Employee Directors (Filed With SEC on February 27, 2019)